Mineralys Therapeutics Stock (NASDAQ: MLYS)

Mineralys Therapeutics

MINERALYS THERAPEUTICS INC

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Stock Movers

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

MLYS

MOMO

MXCT

XPEV

Hello Group, loanDepot, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday&#39;s Pre-Market Session

Biotech

Health Care

General

Mineralys Therapeutics&#39; lorundrostat met key Phase 3 and Phase 2 trial endpoints for hypertension, showing significant blood pressure reductions and a strong safety profile.

Mineralys Therapeutics Unveils Positive Data From Two Trials For Hypertension Drug Candidate

wall street chart shutter2

Earnings

Equities

Eurozone

Commodities

Intraday Update

CKPT

HOOD

NPWR

RDFN

Dow Tumbles Over 600 Points; Mineralys Therapeutics Shares Spike Higher

Mineralys Therapeutics, Inc. - Common Stock

Mineralys Therapeutics Inc

Press Releases

Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on Wednesday, February 12, 2025

Mineralys Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mineralys Therapeutics to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ET

Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension

Mineralys Therapeutics Announces Proposed Public Offering of Common Stock

Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common Stock

Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology's Annual Scientific Session & Expo

Mineralys Therapeutics Announces Closing of Underwriters' Option to Purchase Additional Shares in Connection with Public Offering of Common Stock

Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET

Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's Annual Scientific Session & Expo (ACC.25)

Ardelyx

Anavex Life Sciences Corp. - Common Stock

Anavex Life Sciences

CareDx

Chimerix

Day One Biopharmaceuticals, Inc. - Common Stock

Day One Biopharmaceutical

89bio

Geron

GRAIL

Gyre Therapeutics

Iovance Biotherapeutics, Inc. - Common Stock

Iovance Biotherapeutics

MiMedx Group

Myriad Genetics

Nurix Therapeutics

Intellia Therapeutics, Inc. - Common Stock

Intellia Therapeutics

Novavax

Rocket Pharmaceuticals, Inc. - Common Stock

Rocket Pharmaceuticals

Arcus Biosciences

Replimune Group

Syndax Pharmaceuticals, Inc. - Common Stock

Syndax Pharmaceuticals

ARS Pharmaceuticals

Spyre Therapeutics

Vir Biotechnology

Viridian Therapeutics, Inc. - Common Stock

Viridian Therapeutics

Xencor

Zymeworks

HC Wainwright & Co.

Goldman Sachs

Credit Suisse

Wells Fargo

B of A Securities

Comments

Mineralys Therapeutics

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga